G/TBT/N/CAN/638  
7 April 2021  
(21-2875) Page: 1/2 
Committee on Technical Barriers to Trade  Original:  English /French  
 
  
NOTIFICATION  
The following notification is being circulated in accordance with Article 10.6  
 
1. Notifying Member:  CANADA   
If applicable, name of local government involved (Article 3.2 and 7.2):   
2. Agency responsible:  Health Canada  
Name and address (including telephone and fax numbers , email and website 
addresses, if available) of agency or authority designated to handle comments 
regarding the notification shall be indicated if different from above:   
Canada's Notification Authority a nd Enquiry Point  
Global Affairs Canada  
Technical Barriers and Regulations Division  
111 Sussex Drive  
Ottawa, Ontario, K1A 0G2  
Canada  
Tel: (343)203 -4273  
Fax: 613 -943-0346 
Email: enquirypoint@internati onal.gc.ca  
3. Notified under Article 2.9.2 [X], 2.10.1 [   ], 5.6.2 [   ], 5.7.1 [   ], other :  
4. Products covered (HS or CCCN where applicable, otherwise national tariff 
heading. ICS numbers may be provided in addition, where applicable):  
Prescription status of medicinal ingredients for human use; Other (HS 300490); 
Pharmaceutics (ICS 11.120)  
5. Title, number of pages and language(s) of the notified document:  Notice of Intent 
to Amend: Prescription Drug List (PDL): Tramadol (1 page, avail able in English and 
French)  
6. Description of content:  The purpose of this Notice of Intent to Amend is to notify 
stakeholders that Health Canada will remove tramadol from both the Human and 
Veterinary sections of the Prescription Drug List when the addit ion of tramadol to Schedule 
I to the Controlled Drugs and Substances Act  and to the Narcotic Control Regulations 
comes into force on 31 March 2022.   
7. Objective and rationale, including the nature of urgent problems where 
applicable:  Protection of human health or safety  G/TBT/N/CAN/638  
 
- 2 - 
 
  8. Relevant documents:   
Health  Canada website for the Notice of Intent to Amend, posted 31 March 2021 (available 
in English and French):   
https://www.canada.ca/en/health -canada/services/drugs -health -products/drug -
products/pres cription -drug-list/notices -changes/intent -amendment -tramadol.html  
https://www.canada.ca/fr/sante -canada/services/medicaments -produits -
sante/medicaments/liste -drogues -ordonnance/avis -concernant -modifications/intention -
modification -tramadol.html  
Canada Gazette , Part II, Volume 155, 31 March 2021, pages 690 -722,(availab le in English 
and French): https://canadagazette.gc.ca/rp -pr/p2/2021/2021 -03-31/pdf/g2 -15507.pdf  
9. Proposed date of adoption:  31 March 2021  
Proposed date of entry into force:  31 March 2021  
10. Final date for comments:  Non applicable  
11. Texts available from:  National enquiry point [X] or address, telephone and fax 
numbers and email and website addresses, if available , of other body:   
The electronic version of the regulatory text linked to this notice can be found at:  
https://canadagazette.gc.ca/rp -pr/p2/2021/2021 -03-31/html/sor -dors43 -eng.htm l  
https://canadagazette.gc.ca/rp -pr/p2/2021/2021 -03-31/html/sor -dors44 -eng.html  
https://canadagazette.gc.ca/rp -pr/p2/2021/2021 -03-31/html/sor -dors43 -fra.html   
https://canadagazette.gc.ca/rp -pr/p2/2021/2021 -03-31/html/sor -dors44 -fra.html